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M
alaria remains one of the 
world’s most pressing 
health problems. For many 
populations in tropical countries, the 
disease is a leading cause of mortality 
and morbidity, and more broadly 
constitutes a major impediment 
to development on a number of 
fronts [1]. The few tools presently 
available for control of malaria are 
largely limited to insecticide-treated 
bed nets and treatment of clinical 
episodes with antimalarial drugs. An 
effective malaria vaccine would greatly 
augment these control measures, 
and is probably essential if the global 
burden of malaria is to be markedly 
and sustainably reduced. The absence 
of a vaccine against malaria reﬂ  ects 
the many deﬁ  ciencies in our current 
understanding of the mechanisms 
and targets of immunity to malaria. 
Correlates of immunity to blood-stage 
infection are unclear, as is the nature 
of immune responses that should be 
induced by candidate vaccines.
Challenges in Selecting Suitable 
Vaccine Candidates
There are many reasons why 
identifying the key mediators of 
immunity has been so challenging. 
Plasmodium falciparum, the major cause 
of malaria, is a complex organism 
presenting numerous antigens that 
could feasibly be targets of protective 
responses. Moreover, antigens are 
often polymorphic, and in some cases, 
they exhibit clonal variation through 
differential expression of multi-gene 
family members. During blood-stage 
infection, when disease occurs, P. 
falciparum resides in erythrocytes, cells 
that lack major histocompatibility 
complex molecules on their surface 
and which are therefore not directly 
targeted by T lymphocytes. The process 
of erythrocyte invasion is complex 
and involves many receptor–ligand 
interactions with a signiﬁ  cant degree of 
redundancy; blocking one ligand can 
be circumvented by the use of others 
[2]. In addition, expression and correct 
folding of recombinant P. falciparum 
antigens has also proved a signiﬁ  cant 
roadblock. 
MSP-3—An Encouraging Vaccine 
Target
Despite these challenges, several 
antigens expressed by merozoites, the 
extracellular form of the parasite that 
infects erythrocytes, have emerged as 
promising vaccine candidates. Pierre 
Druilhe and colleagues now present 
encouraging ﬁ  ndings from a phase 
I trial of merozoite surface protein 
(MSP) 3 [3]. A number of studies have 
supported the potential development 
of MSP-3 as a vaccine since its discovery 
[4], including associations between 
MSP-3 antibodies and acquired 
immunity in population studies (see 
references cited in [3]). The vaccine 
is based on a highly conserved region 
of the protein, and is produced as a 
synthetic peptide, incorporating both 
T and B cell epitopes. Immunization 
of naïve volunteers was performed with 
two different adjuvants, Montanide 
ISA720 and alum, and with different 
antigen doses. 
Testing for Functional Immunity
Besides standard evaluation of 
safety and immunogenicity of the 
vaccine, Druilhe and colleagues also 
demonstrated that vaccine recipients 
who seroconverted had substantial 
parasite growth inhibitory activity 
in antibody-dependent cellular 
inhibition (ADCI) assays. In these 
functional assays, serum antibodies are 
incubated with parasites, together with 
monocytes, in vitro (the monocytes 
are necessary for parasite growth 
inhibition, but their precise role is not 
understood). Some 60% of individuals 
who received the three-dose regimen 
generated antibodies that recognize 
the native MSP-3 protein, and there 
was a strong association between MSP-3 
antibody positivity and possession of 
ADCI activity. This strong association 
is particularly encouraging, and 
supports the premise that ADCI activity 
is antigen speciﬁ  c. In this regard, it is 
interesting that MSP-3 has emerged 
as just one member of the family of 
merozoite proteins that can loosely be 
regarded as “MSP-3–like” proteins, all 
of which are encoded in a gene cluster 
on Chromosome 10 [5]. Druilhe and 
colleagues suggest that MSP-3 family 
members, such as MSP-6, possess cross-
reactive ADCI epitopes; therefore, 
antibodies elicited by the vaccine 
probably have multiple parasite targets. 
As MSP-3 is not essential to blood-stage 
development of the parasite, at least in 
vitro [6], cross-reactivity of protective 
antibodies induced by the MSP-3 
vaccine with other targets is highly 
desirable. To address this issue, the 
activity and speciﬁ  city of the vaccine-
induced response could be explored 
further through the use of an MSP-3 
“knockout” parasite line [6]. 
The researchers also used a novel 
approach to demonstrate antimalarial 
activity of vaccine-induced antibodies 
in vivo. Severely immunocompromised 
mice grafted with human blood cells 
sustain experimental infections with P. 
falciparum (in contrast to normal mice, 
which are resistant to P. falciparum 
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infection). Injection of human 
monocytes from nonvaccinated donors 
and of antibodies from seropositive 
vaccine recipients led to clearance of 
parasitemia in this humanized mouse 
model, analogous to results achieved 
with in vitro ADCI assays. While the 
relevance of this model to immunity 
in human infections remains unclear, 
these results provide another positive 
indicator of an antiparasitic effect for 
the vaccine-induced MSP-3 antibodies. 
Signiﬁ  cantly, parasite inhibitory 
activity in ADCI assays was still detected 
among many volunteers at 12 months 
postvaccination, particularly among 
those vaccinated with alum as the 
adjuvant. The vaccine also induced 
IFNγ T cell responses, and this type 
of response has been associated with 
protective immunity in studies of 
natural and experimental infection in 
humans [7,8]. 
Moving Forward
It is becoming increasingly clear that 
functional assays to study vaccine-
induced responses are essential. 
Examining seroconversion by enzyme-
linked immunosorbent assay or 
immunoﬂ  uorescence using whole 
parasites is not sufﬁ  ciently informative, 
and several recent studies have 
demonstrated limitations of standard 
assays. For example, antibodies to 
MSP-1 do not necessarily inhibit P. 
falciparum replication, and worse, some 
antibodies appear able to block the 
action of inhibitory antibodies [9]. 
A longitudinal study in Kenya found 
that antibodies to recombinant MSP-
1 were not associated with protective 
immunity, whereas MSP-1–speciﬁ  c 
growth inhibitory antibodies were 
predictive [10]. 
As intimated above, a particular 
strength of the MSP-3 trial is that 
functional assays were utilized to assess 
the quality of the antibody response 
produced. However, it remains 
unclear if ADCI is a major mechanism 
of parasite clearance capable of 
conferring protective immunity in 
exposed individuals. Such studies have 
been hampered somewhat because, 
like most functional assays, ADCI assays 
are technically challenging. Moreover, 
immune individuals have also been 
shown to possess inhibitory antibodies 
that do not require cooperation with 
monocytes; rather, they directly inhibit 
erythrocyte invasion and parasite 
replication [11,12]. Ultimately, the 
protective effect of MSP-3–speciﬁ  c 
antibodies and ADCI needs to be 
evaluated in an efﬁ  cacy-based clinical 
trial of this vaccine.  
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